Literature DB >> 21995180

Prevalence of uncontrolled severe persistent asthma in pneumology and allergy hospital units in Spain.

S Quirce1, V Plaza, C Picado, M Vennera, J Casafont.   

Abstract

BACKGROUND: Severe persistent asthma is often poorly controlled and its prevalence in pneumology and allergy hospital units in Spain is unknown.
OBJECTIVES: To determine the prevalence of uncontrolled severe persistent asthma in hospital units in Spain and to describe the clinical characteristics of this condition.
METHODS: An observational, cross-sectional study was conducted in 164 Spanish hospital pneumology and allergology units. A record was made of all patients with asthma and patients with uncontrolled severe asthma (diagnosed on the basis of clinical criteria) seen in these units over 6 months. Information on sociodemographic variables, clinical characteristics, pharmacological asthma treatment, skin prick testing, total serum immunoglobulin E (IgE) levels, pulmonary function (forced expiratory volume in the first second and forced vital capacity), asthma control (Asthma Control Questionnaire [ACQ]), and quality of life (Asthma Quality of Life Questionnaire) was collected.
RESULTS: According to the clinicians' judgement, 1423 out of 36 649 asthma patients (3.9%, 95% confidence interval, 3.7%-4.1%]) had uncontrolled severe persistent asthma.These patients had a mean (SD) ACQ score of 3.8 (1.0); 55.8% had a positive skin prick test to common aeroallergens and 54.2% had high levels of total serum IgE.The agreement between the assessment of asthma control based on clinicians' criteria and according to the Global Initiative forAsthma (GINA) guidelines was moderate (63.2%, Kic = 0.337), with an underestimation of asthma severity by clinicians; 53.2% of the patients classified as having controlled moderate to severe asthma had uncontrolled severe persistent asthma according to GINA criteria.
CONCLUSIONS: There is a low prevalence of uncontrolled severe persistent asthma in patients seen at hospital units in Spain according to clinical criteria, although it should be noted that level of asthma control is overestimated by clinicians.

Entities:  

Mesh:

Year:  2011        PMID: 21995180

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  11 in total

1.  Factors Contributing Towards Poor Asthma Control in Patients on Regular Medication.

Authors:  Siddharth Gosavi; Pratibha Nadig; Alamelu Haran
Journal:  J Clin Diagn Res       Date:  2016-06-01

2.  Therapeutic options for severe asthma.

Authors:  Jilcy Mathew; Wilbert S Aronow; Dipak Chandy
Journal:  Arch Med Sci       Date:  2012-09-08       Impact factor: 3.318

3.  Accreditation of specialized asthma units for adults in Spain: an applicable experience for the management of difficult-to-control asthma.

Authors:  Carolina Cisneros; Rocío Magdalena Díaz-Campos; Núria Marina; Carlos Melero; Alicia Padilla; Silvia Pascual; Celia Pinedo; Andrea Trisán
Journal:  J Asthma Allergy       Date:  2017-05-09

Review 4.  The Global Impact of Asthma in Adult Populations.

Authors:  Oladunni Enilari; Sumita Sinha
Journal:  Ann Glob Health       Date:  2019-01-22       Impact factor: 2.462

5.  [Asthma control in patients attending primary care in Spain (Actis study)].

Authors:  Eduardo Calvo; Juan A Trigueros; Araceli López; Guadalupe Sánchez
Journal:  Aten Primaria       Date:  2017-04-12       Impact factor: 1.137

6.  Is a mobile application useful for patients with moderate-severe asthma?

Authors:  Sonia Herrero Martín; Javier Hueto Pérez de Heredia; Alberto Cuesta Remón; Marisol Gómez Fernández; María M Antón; Juan Cabasés; Ruth García Rey; Pilar Cebollero Rivas
Journal:  Arch Bronconeumol       Date:  2021-06-16       Impact factor: 6.333

7.  The impact of COVID-19 on patients with asthma.

Authors:  José Luis Izquierdo; Carlos Almonacid; Yolanda González; Carlos Del Rio-Bermudez; Julio Ancochea; Remedios Cárdenas; Sara Lumbreras; Joan B Soriano
Journal:  Eur Respir J       Date:  2021-03-04       Impact factor: 16.671

Review 8.  Evaluation and Management of Difficult-to-Treat and Severe Asthma: An Expert Opinion From the Korean Academy of Asthma, Allergy and Clinical Immunology, the Working Group on Severe Asthma.

Authors:  Byung Keun Kim; So Young Park; Ga Young Ban; Mi Ae Kim; Ji Hyang Lee; Jin An; Ji Su Shim; Youngsoo Lee; Ha Kyeong Won; Hwa Young Lee; Kyoung Hee Sohn; Sung Yoon Kang; So Young Park; Hyun Lee; Min Hye Kim; Jae Woo Kwon; Sun Young Yoon; Jae Hyun Lee; Chin Kook Rhee; Ji Yong Moon; Taehoon Lee; So Ri Kim; Jong Sook Park; Sang Heon Kim; Heung Woo Park; Jae Won Jeong; Sang Hoon Kim; Young Il Koh; Yeon Mok Oh; An Soo Jang; Kwang Ha Yoo; You Sook Cho
Journal:  Allergy Asthma Immunol Res       Date:  2020-11       Impact factor: 5.764

9.  Asthma Control in Patients with Severe Eosinophilic Asthma Treated with Reslizumab: Spanish Real-Life Data.

Authors:  Luis A Pérez de Llano; Borja G Cosío; Ignacio Lobato Astiárraga; Gregorio Soto Campos; Miguel Ángel Tejedor Alonso; Nuria Marina Malanda; Alicia Padilla Galo; Isabel Urrutia Landa; Francisco J Michel de la Rosa; Ismael García-Moguel
Journal:  J Asthma Allergy       Date:  2022-01-14

10.  Characteristics and treatment patterns of patients with asthma on multiple-inhaler triple therapy in Spain.

Authors:  Miriam Barrecheguren; Monica Monteagudo; Marc Miravitlles; Xavier Flor; Alexa Núñez; Jeisson Osorio; Xavier Muñoz; Iñigo Ojanguren
Journal:  NPJ Prim Care Respir Med       Date:  2022-03-10       Impact factor: 2.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.